PainResearch Phase

Met-Enkephalin

Endogenous peptide

Overview

Met-enkephalin is a pentapeptide (Tyr-Gly-Gly-Phe-Met) that differs from leu-enkephalin only in its C-terminal amino acid. It acts as an endogenous opioid with preferential delta-opioid receptor activity and also binds mu-opioid receptors.

Mechanism of Action

Derived from proenkephalin, met-enkephalin is involved in pain modulation, stress responses, and immune regulation. Like other enkephalins, it is subject to rapid enzymatic degradation by aminopeptidases and enkephalinases..

Research Summary & Key Findings

Met-enkephalin has been characterized in numerous preclinical studies demonstrating analgesic and neuromodulatory effects when central degradation is prevented. Clinical translation has been hindered by the peptide's instability and inability to cross the blood-brain barrier. Synthetic analogs with enhanced stability, such as DADLE, have been investigated but have not achieved widespread clinical use.

Clinical Status

Research Phase

Met-Enkephalin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Endogenous peptide

Related Peptides in Pain

Find a Provider

Find a verified provider who offers Met-Enkephalin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Met-Enkephalin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.